Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease: Survival Estimates From the EMPA-REG OUTCOME Trial

被引：32
|
作者：
Claggett, Brian [1 ]
Lachin, John M. [2 ]
Hantel, Stefan [3 ]
Fitchett, David [4 ,5 ]
Inzucchi, Silvio E. [6 ]
Woerle, Hans J. [7 ]
George, Jyothis T. [7 ]
Zinman, Bernard [5 ,8 ]
机构：
[1] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
[2] George Washington Univ, Biostat Ctr, Rockville, MD USA
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[4] St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Yale Univ, Endocrinol Sect, Sch Med, New Haven, CT USA
[7] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[8] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
CIRCULATION | 2018年 / 138卷 / 15期
关键词：
cardiovascular diseases; diabetes mellitus; empagliflozin;
D O I：
10.1161/CIRCULATIONAHA.118.033810
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1599 / 1601
页数：3
相关论文
共 50 条
  • [11] Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
    Sharma, Abhinav
    Inzucchi, Silvio E.
    Testani, Jeffery
    Ofstad, Anne Pernille
    Fitchett, David
    Mattheus, Michaela
    Verma, Subodh
    Zannad, Faiez
    Wanner, Christoph
    Kraus, Bettina
    INTERNIST, 2022, 63 (SUPPL 3): : 316 - 316
  • [12] Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
    Verma, Subodh
    Mazer, C. David
    Bhatt, Deepak L.
    Raj, Satish R.
    Yan, Andrew T.
    Verma, Atul
    Ferrannini, Ele
    Simons, Gudrun
    Lee, Jisoo
    Zinman, Bernard
    George, Jyothis T.
    Fitchett, David
    DIABETES CARE, 2019, 42 (03) : E42 - E44
  • [13] Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial
    Sharma, A.
    Inzucchi, S. E.
    Testani, J.
    Ofstad, A. P.
    Fitchett, D.
    Mattheus, M.
    Verma, S.
    Zannad, F.
    Wanner, C.
    Kraus, B. J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 175 - 175
  • [14] Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
    Vaduganathan, Muthiah
    Sattar, Naveed
    Fitchett, David H.
    Ofstad, Anne Pernille
    Brueckmann, Martina
    George, Jyothis T.
    Verma, Subodh
    Mattheus, Michaela
    Wanner, Christoph
    Inzucchi, Silvio E.
    Zinman, Bernard
    Butler, Javed
    DIABETES, 2020, 69
  • [15] Long-Term Economic Outcomes of Empagliflozin (Jardiance) Treatment in Type 2 Diabetes Mellitus (T2DM) based on the EMPA-REG Outcome Trial
    Kansal, Anuraag R.
    Zheng, Ying
    Proskorovsky, Irina
    Reifsnider, Odette
    Kandaswamy, Prashanth
    Ruffolo, Antonio
    DIABETES, 2016, 65 : A326 - A326
  • [16] Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOMEA®
    Zinman, Bernard
    Inzucchi, Silvio E.
    Wanner, Christoph
    Hehnke, Uwe
    George, Jyothis T.
    Johansen, Odd Erik
    Fitchett, David
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    Strivay, M.
    Vereecken, G.
    Keymeulen, B.
    DIABETOLOGIA, 2018, 61 (07) : 1522 - 1527
  • [17] Empagliflozin Exerts Short- and Long-term Effects on Plasma Volume in Patients With Type 2 Diabetes: Insight From EMPA-REG OUTCOME
    Schou, Morten
    Gullestad, Lars
    Fitchett, David
    Zinman, Bernard
    Inzucchi, Silvio E.
    Hehnke, Uwe
    von Eynatten, Max
    George, Jyothis
    Johansen, Odd Erik
    Wanner, Christoph
    CIRCULATION, 2017, 136
  • [18] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
    Fitchett, David
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Hantel, Stefan
    Salsali, Afshin
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    EUROPEAN HEART JOURNAL, 2016, 37 (19) : 1526 - 1534
  • [19] Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial
    Odutayo, Ayodele
    Zinman, Bernard
    Wanner, Christoph
    Zwiener, Isabella
    Lund, Soren S.
    Hantel, Stefan
    Fitchett, David
    Udell, Jacob A.
    CJC OPEN, 2024, 6 (07) : 868 - 875
  • [20] Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
    Wanner, Christoph
    Heerspink, Hiddo J. L.
    Zinman, Bernard
    Inzucchi, Silvio E.
    Koitka-Weber, Audrey
    Mattheus, Michaela
    Hantel, Stefan
    Woerle, Hans-Juergen
    Broedl, Uli C.
    von Eynatten, Maximilian
    Groop, Per-Henrik
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 29 (11): : 2755 - 2769
12345